Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Abivax SA (OTC: AAVXF).

Full DD Report for AAVXF

Recent News from (OTC: AAVXF)

Abivax SA reports 1H results
Abivax SA ( OTCPK:AAVXF ): 1H Net loss of €5.55 More news on: Abivax SA, Earnings news and commentary, , Read more ...
Source: SeekingAlpha
Date: September, 20 2017 12:39
Abivax: A Biotech With Blockbuster Potential
Abivax (AAVXF) has developed a unique antiviral delivery platform using ingenious science to infiltrate cells and prevent replication of viruses. Their current top line drug, Abivax 464 has shown remarkable results in a just completed clinical Phase II trial of depleting HIV reservoirs with ...
Source: SeekingAlpha
Date: May, 25 2017 14:55
Abivax Not Getting Ahead Of Itself In HIV Chase
A doubling in valuation based on positive trial data is the sort of catalyst many small biotechs use to raise a new pile of money. Not so the French antiviral specialist Abivax (AAVXF), which is taking a deliberate approach after an early phase II trial found evidence that ABX-464 reduces HIV ...
Source: SeekingAlpha
Date: May, 22 2017 13:36
Snippet Roundup: Novartis' Allogeneic CAR-T Drive And Astra's IL-4 Interest
Welcome to your weekly roundup of EP Vantage's snippets - short takes on smaller news items. This week, May 1 to 5, 2017, we had thoughts on the following: Outset sets out for market with $77m; Livanova gets into mitral; Astra (AZN) signals interest in high risk asthma target; Novartis (NVS)...
Source: SeekingAlpha
Date: May, 05 2017 15:30
Abivax (AAVXF) Presents HIV Clinical Trial Data ABX464 - Slideshow
The following slide deck was published by Abivax SA in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 02 2017 13:23
Abivax soars on HIV results
Phase IIa results show ABX464 has potential to become a “key functional cure element” for HIV,  Abivax ( OTC:AAVXF ) says in a statement . More news on: Abivax SA, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 02 2017 11:04
Abivax SA reports FY results
Abivax SA ( OTC:AAVXF ): FY net loss of -€14.30 Revenue of €$0.2M (flat Y/Y) Press Release More news on: Abivax SA, Earnings news and commentary, ,
Source: SeekingAlpha
Date: March, 15 2017 15:13
Abivax Aims High In HIV Care
In the absence of a cure, advances in HIV treatment have centred on limiting resistance and reducing side effects. French biotech Abivax (AAVXF) is hoping its novel approach disrupting viral RNA splicing can not only reduce viral load but also reduce cellular reservoirs. Backed by the larges...
Source: SeekingAlpha
Date: October, 14 2016 13:46


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About Abivax SA (OTC: AAVXF)

Logo for Abivax SA (OTC: AAVXF)

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral and inflammatory disease.


Contact Information



Current Management

  • Hartmut J. Ehrlich / CEO
  • Didier Blondel / CFO
  • Philippe Pouletty / Chairman
  • Joy A. Amundson /
  • JeanJacques Bertran /
  • Claude Bertrand /
  • Dominique Costantini /
  • Antonino Ligresti /
  • Antoine Pau /
  • Christian Pierret /
  • JeanPaul Prieels /

Current Share Structure

  • Market Cap: $96,046,260 - 03/20/2018
  • Issue and Outstanding: 9,741,000 - 12/31/2016


Daily Technical Chart for (OTC: AAVXF)

Daily Technical Chart for (OTC: AAVXF)

Stay tuned for daily updates and more on (OTC: AAVXF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AAVXF)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

Monsta Trader



Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AAVXF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AAVXF and does not buy, sell, or trade any shares of AAVXF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer:



Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us